Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?

NCT ID NCT05204927

Ongoing Disease control Sponsor: Curium US LLC Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether a new type of targeted radiation therapy, called 177Lu-PSMA-I&T, can slow the progression of metastatic castration-resistant prostate cancer better than standard hormone therapy. The study enrolls men with prostate cancer that has spread and no longer responds to hormone treatment. Participants are randomly assigned to receive either the radioligand therapy or a hormone therapy (abiraterone with prednisone, or enzalutamide). The main goal is to see how long the cancer stays under control before it progresses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-I&T, a radioligand therapy that delivers targeted radiation to prostate cancer cells
What this could lead to: If successful, this could offer a new, more effective treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is a phase 3 trial, but results are not guaranteed. The treatment may not prove superior to hormone therapy, and radiation therapy carries risks like damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTASIS FROM MALIGNANT TUMOR OF PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTASIS FROM MALIGNANT TUMOR OF PROSTATE

Contacts and locations

Locations

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy
Arizona Institute of Urology, PPLC

Tucson, Arizona, 85704, United States
BAMF Health I PC

Grand Rapids, Michigan, 49503, United States
Biogenix Molecular LLC

Miami, Florida, 33165, United States
CHU Brest

Brest, France
CHU Nimes

Nîmes, France
Center for Clinical Theranostics Research, Washington University

St Louis, Missouri, 63110, United States
Central Ohio Urology Group

Gahanna, Ohio, 43230, United States
Columbia University Medical Center - Herbert Irving Pavilion

New York, New York, 10032, United States
Florida Urology Partners, LLP

Tampa, Florida, 33607, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Fundación Jiménez Díaz

Madrid, Spain
GenesisCare USA

Boca Raton, Florida, 33431, United States
GenesisCare USA

Plantation, Florida, 33324, United States
GenesisCare USA

Troy, Michigan, 48098, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Hightower Clinical

Oklahoma City, Oklahoma, 73102, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Hospital Regional Universitario de Malaga

Málaga, Spain
Hospital Universitario HM Sanchinarro

Madrid, Spain
Houston Metro Urology

Houston, Texas, 77027, United States
Hôpital de Brabois -CHU

Nancy, France
ICANS

Strasbourg, France
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Institut de Cancérologie de l'Ouest (ICO) St Herblain

Nantes, France
InstitutClaudius Regaud-IUCT-O

Toulouse, France
Institute Paoli-Calmettes

Marseille, France
Istituto Europeo di Oncologia (IEO) -IRCCS

Milan, Italy
Jean Perrin Comprehensive Cancer Center

Clermont-Ferrand, France
John Hopkins Hospital

Baltimore, Maryland, 21287, United States
Kaiser Permanente Gaithersburg Medical Center

Gaithersburg, Maryland, 20879, United States
Long Beach Memorial Center

Long Beach, California, 90806, United States
M Health Fairview Ridges Cancer Clinic

Burnsville, Minnesota, 55337, United States
Michigan Institute of Urology

Troy, Michigan, 48084, United States
MidLantic Urology

Bala-Cynwyd, Pennsylvania, 19004, United States
NorthShore University HealthSystem-Evanston Hospital

Evanston, Illinois, 60201, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
OHSU - Center for health and healing

Portland, Oregon, 97239, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists

Omaha, Nebraska, 68130, United States
Orlando Health Cancer Institute

Orlando, Florida, 32806, United States
Providence Medical Foundation

Fullerton, California, 92835, United States
Providence Saint John's Health Center

Santa Monica, California, 90404, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08993, United States
SSM Saint Louis University Hospital

St Louis, Missouri, 63104, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States
San Francisco VA Health Care System

San Francisco, California, 94121, United States
University Clinic Bologna

Bologna, Italy
University Hospital of Salamanca

Salamanca, Spain
University of California, San Francisco

San Francisco, California, 94158, United States
Urology San Antonio

San Antonio, Texas, 78229, United States
VA Portland Health Care System

Portland, Oregon, 97239, United States
XCancer Omaha / Urology Cancer Center

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.